Blog
RSS FeedPosted by Michael Wonder on 30 Oct 2023
ICER publishes final evidence report on gene therapy for metachromatic leukodystrophy
30 October 2023 - Independent appraisal committee voted that across all patient sub-populations, arsa-cel demonstrated a net health benefit when ...
Posted by Michael Wonder on 14 Sep 2023
ICER publishes evidence report on gene therapy for metachromatic leukodystrophy
14 September 2023 - Using weighted analyses across all patient subpopulations, atidarsagene autotemcel would achieve common thresholds for cost effectiveness if priced ...
Posted by Michael Wonder on 21 Aug 2023
ICER publishes final evidence report on gene therapies for sickle cell disease
21 August 2023 - Current evidence suggests that lovo-cel and exa-cel would achieve common thresholds for cost-effectiveness if priced between $1.35 ...
Posted by Michael Wonder on 13 Jul 2023
ICER publishes evidence report on gene therapies for sickle cell disease
13 July 2023 - In the short term, both lovo-cel and exa-cel can dramatically reduce the frequency of painful crises ...
Posted by Michael Wonder on 03 Jun 2023
America will struggle to pay for ultra-expensive gene therapies
1 June 2023 - The drugs may force reform to Medicaid. ...
Posted by Michael Wonder on 12 Apr 2023
ICER releases draft evidence report on gene therapies for sickle cell disease
12 April 2023 - Public comment period now open until 9 May 2023; Requests to make oral comment during public ...
Posted by Michael Wonder on 10 Mar 2023
ICER to assess gene therapy for metachromatic leukodystrophy
9 March 2023 - Report will be subject of CTAF meeting in September 2023; draft scoping document open to public ...
Posted by Michael Wonder on 22 Dec 2022
ICER publishes final evidence report on gene therapies for haemophilia A and B
22 December 2022 - Fair pricing benchmarks suggest upper bounds for price of Roctavian at approximately $1.9 million and for Hemgenix ...
Posted by Michael Wonder on 23 Nov 2022
ICER to assess gene therapies for sickle cell disease
23 November 2022 - Report will be subject of CTAF meeting in June 2023; draft scoping document open to public ...
Posted by Michael Wonder on 02 Nov 2022
ICER publishes evidence report on gene therapies for haemophilia A and B
2 November 2022 - Duration of benefit with gene therapies and risks for rare side effects remain major uncertainties. ...
Posted by Michael Wonder on 13 Sep 2022
ICER releases draft evidence report on gene therapies for haemophilia A and B
13 September 2022 - Registration now open for 20 September “Early Insights” webinar. ...
Posted by Michael Wonder on 19 Jul 2022
ICER publishes final evidence report and policy recommendations on beti-cel gene therapy for beta thalassaemia
19 July 2022 - Independent appraisal committee unanimously determined that evidence is adequate to demonstrate that beti-cel provides a net ...
Posted by Michael Wonder on 02 Jun 2022
ICER publishes evidence report on gene therapy for beta thalassaemia
2 June 2022 - Evidence judged to demonstrate that beti-cel provides net health benefit to patients with transfusion-dependent thalassaemia. ...
Posted by Michael Wonder on 05 May 2022
ICER to assess gene therapies for haemophilia A and B
5 May 2022 - Report will be subject of CTAF meeting in November 2022; draft scoping document open to public ...
Posted by Michael Wonder on 05 May 2022
ICER’s favourable assessment of Bluebird Bio’s gene therapy Zynteglo may have important pricing and reimbursement implications
5 May 2022 - ICER evaluated the clinical and cost-effectiveness - as well as budgetary impact - of one of two ...